Why the study?
Does aggressive combined modality therapy improve survival in patients with inflammatory breast cancer compared to surgery or irradiation alone?
Does aggressive combined modality therapy improve survival in patients with inflammatory breast cancer compared to surgery or irradiation alone?
Inflammatory breast cancer requires aggressive combined modality therapy (chemotherapy, surgery, and irradiation) to prolong survival, as it is a systemic disease.
Answers are grounded in this paper and cite their sources.
Supports aggressive combined modality therapy in inflammatory breast cancer; leaves open need for randomized confirmation.
Inflammatory breast cancer is the most aggressive breast neoplasm and one of the most ominous solid tumors. Because of distinct clinical characteristics, diagnosis can usually be made on clinical grounds. Biopsy including the overlying skin may demonstrate dermal lymphatic invasion, although the absence of dermal lymphatic invasions should not deter aggressive therapy. Surgery or irradiation alone has little effect on the natural history of this disease since lymphatic invasion and distant metastases are often present at presentation. Inflammatory breast cancer should be considered a systemic disease. Accordingly, aggressive combined modality therapy including multi-drug chemotherapy, surgery, and irradiation have prolonged disease-free survival and overall survival.
No takes yet. Share an insight, caveat, or question.
Ellis et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: